Hearing Loss in a Patient with Waldenstrom Macroglobulinemia Receiving Bortezomib.

IF 0.7 Q4 ONCOLOGY Case Reports in Oncology Pub Date : 2024-06-18 eCollection Date: 2024-01-01 DOI:10.1159/000539453
Jack Fitzsimons, Kathleen Phelan, Asha Dhanarajan
{"title":"Hearing Loss in a Patient with Waldenstrom Macroglobulinemia Receiving Bortezomib.","authors":"Jack Fitzsimons, Kathleen Phelan, Asha Dhanarajan","doi":"10.1159/000539453","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>We present a case report of hearing loss in a patient with Waldenstrom macroglobulinemia (WM) receiving treatment with bortezomib.</p><p><strong>Case presentation: </strong>Our patient developed sudden bilateral sensorineural hearing loss after receiving three doses of bortezomib. His hearing loss was irreversible and resulted in a cochlear implant.</p><p><strong>Conclusion: </strong>Hearing loss secondary to bortezomib is a known, but very rare, side effect. Hearing loss secondary to WM is also rare and has been described in case reports.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"653-657"},"PeriodicalIF":0.7000,"publicationDate":"2024-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11249454/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000539453","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: We present a case report of hearing loss in a patient with Waldenstrom macroglobulinemia (WM) receiving treatment with bortezomib.

Case presentation: Our patient developed sudden bilateral sensorineural hearing loss after receiving three doses of bortezomib. His hearing loss was irreversible and resulted in a cochlear implant.

Conclusion: Hearing loss secondary to bortezomib is a known, but very rare, side effect. Hearing loss secondary to WM is also rare and has been described in case reports.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
接受硼替佐米治疗的瓦尔登斯特罗姆巨球蛋白血症患者的听力损失。
导言:我们报告了一例正在接受硼替佐米治疗的瓦尔登斯特罗姆巨球蛋白血症(WM)患者听力损失的病例:我们的患者在接受了三次硼替佐米治疗后突然出现双侧感音神经性听力损失。他的听力损失是不可逆的,因此需要植入人工耳蜗:结论:硼替佐米继发听力损失是一种已知但非常罕见的副作用。结论:硼替佐米继发听力损失是一种已知但非常罕见的副作用,继发于 WM 的听力损失也很罕见,在病例报告中已有描述。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
1.40
自引率
12.50%
发文量
151
审稿时长
7 weeks
期刊最新文献
Long-Term Survival after Stereotactic Radiotherapy Combined with Immunotherapy in a Patient with Recurrent Oral Cancer. Nasopharyngeal Metastasis from Lung Adenocarcinoma: A Case Report and Literature Review. Atypical Presentation of an Ovarian Yolk Sac Tumor in an 80-Year-Old Woman: A Case Report and Review of the Literature. Warm Autoimmune Hemolytic Anemia as First Presentation of Chronic Myeloid Leukemia: A Case Report. Pelvic/Sacral Chondrosarcoma with Brain Metastasis: A Case Report.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1